233 related articles for article (PubMed ID: 35970825)
1. Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands.
Zhong J; Yang X; Chen J; He K; Gao X; Wu X; Zhang M; Zhou H; Xiao F; An L; Wang X; Shi Y; Zhang N
Nat Commun; 2022 Aug; 13(1):4795. PubMed ID: 35970825
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
Bugide S; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
[TBL] [Abstract][Full Text] [Related]
3. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
4. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
5. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
6. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
[TBL] [Abstract][Full Text] [Related]
7. Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.
Vulpis E; Loconte L; Cassone C; Antonangeli F; Caracciolo G; Masuelli L; Fazio F; Petrucci MT; Fionda C; Soriani A; Cerboni C; Cippitelli M; Santoni A; Zingoni A
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298418
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
[TBL] [Abstract][Full Text] [Related]
9. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
10. MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells.
Morimoto Y; Yamashita N; Daimon T; Hirose H; Yamano S; Haratake N; Ishikawa S; Bhattacharya A; Fushimi A; Ahmad R; Takahashi H; Dashevsky O; Mitsiades C; Kufe D
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754452
[TBL] [Abstract][Full Text] [Related]
11. Expression profiles of Natural Killer Group 2D Ligands (NGK2DLs) in colorectal carcinoma and changes in response to chemotherapeutic agents.
Kucuk B; Yilmaz E; Cacan E
Mol Biol Rep; 2021 May; 48(5):3999-4008. PubMed ID: 34009568
[TBL] [Abstract][Full Text] [Related]
12. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
[TBL] [Abstract][Full Text] [Related]
13. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.
Sutherland CL; Rabinovich B; Chalupny NJ; Brawand P; Miller R; Cosman D
Blood; 2006 Aug; 108(4):1313-9. PubMed ID: 16621962
[TBL] [Abstract][Full Text] [Related]
14. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.
Cosman D; Müllberg J; Sutherland CL; Chin W; Armitage R; Fanslow W; Kubin M; Chalupny NJ
Immunity; 2001 Feb; 14(2):123-33. PubMed ID: 11239445
[TBL] [Abstract][Full Text] [Related]
15. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.
Sutherland CL; Chalupny NJ; Cosman D
Immunol Rev; 2001 Jun; 181():185-92. PubMed ID: 11513139
[TBL] [Abstract][Full Text] [Related]
16.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
17. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.
Paczulla AM; Rothfelder K; Raffel S; Konantz M; Steinbacher J; Wang H; Tandler C; Mbarga M; Schaefer T; Falcone M; Nievergall E; Dörfel D; Hanns P; Passweg JR; Lutz C; Schwaller J; Zeiser R; Blazar BR; Caligiuri MA; Dirnhofer S; Lundberg P; Kanz L; Quintanilla-Martinez L; Steinle A; Trumpp A; Salih HR; Lengerke C
Nature; 2019 Aug; 572(7768):254-259. PubMed ID: 31316209
[TBL] [Abstract][Full Text] [Related]
18. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
[TBL] [Abstract][Full Text] [Related]
19. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation.
Fielding CA; Aicheler R; Stanton RJ; Wang EC; Han S; Seirafian S; Davies J; McSharry BP; Weekes MP; Antrobus PR; Prod'homme V; Blanchet FP; Sugrue D; Cuff S; Roberts D; Davison AJ; Lehner PJ; Wilkinson GW; Tomasec P
PLoS Pathog; 2014 May; 10(5):e1004058. PubMed ID: 24787765
[TBL] [Abstract][Full Text] [Related]
20. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients.
Crane CA; Austgen K; Haberthur K; Hofmann C; Moyes KW; Avanesyan L; Fong L; Campbell MJ; Cooper S; Oakes SA; Parsa AT; Lanier LL
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12823-8. PubMed ID: 25136121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
